Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective …
Background Conventional imaging using CT and bone scan has insufficient sensitivity
when staging men with high-risk localised prostate cancer. We aimed to investigate whether …
when staging men with high-risk localised prostate cancer. We aimed to investigate whether …
[HTML][HTML] Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging …
Purpose Recent advances in imaging, use of prognostic indices, and molecular profiling
techniques have the potential to improve disease characterization and outcomes in lymphoma. …
techniques have the potential to improve disease characterization and outcomes in lymphoma. …
[PDF][PDF] Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in …
… Cremerius U, Fabry U, Neuerburg J, et al: Prognostic significance of positron emission
tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant …
tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant …
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Background Progressive metastatic castration-resistant prostate cancer is a highly lethal
disorder and new effective therapeutic agents that improve patient outcomes are urgently …
disorder and new effective therapeutic agents that improve patient outcomes are urgently …
Delivering affordable cancer care in high-income countries
…, D Verellen, T Roberts, G Storme, RJ Hicks… - The lancet …, 2011 - thelancet.com
The burden of cancer is growing, and the disease is becoming a major economic expenditure
for all developed countries. In 2008, the worldwide cost of cancer due to premature death …
for all developed countries. In 2008, the worldwide cost of cancer due to premature death …
Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer …
Purpose To determine the association between tumor hypoxia, treatment regimen, and
locoregional failure (LRF) in patients with stage III or IV squamous cell carcinoma of the head and …
locoregional failure (LRF) in patients with stage III or IV squamous cell carcinoma of the head and …
Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients …
MP Mac Manus, RJ Hicks, JP Matthews… - Journal of Clinical …, 2003 - ascopubs.org
Purpose: To prospectively study the capacity of positron emission tomography (PET) and
computed tomography (CT) to determine response soon after radical radiotherapy or …
computed tomography (CT) to determine response soon after radical radiotherapy or …
Evaluation of circulating tumor cells and circulating tumor DNA in non–small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of …
…, W Liu, R Raja, BM Fine, BGM Hughes, RJ Hicks… - Clinical Cancer …, 2012 - AACR
Purpose: Elevated levels or increases in circulating tumor cells (CTC) portend poor prognosis
in patients with epithelial cancers. Less is known about CTCs as surrogate endpoints or …
in patients with epithelial cancers. Less is known about CTCs as surrogate endpoints or …
Somatostatin Receptor Imaging with 68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation
Gallium 68 ( 68 Ga) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)–octreotate
(DOTATATE, GaTate) positron emission tomography (PET)/computed tomography (CT) …
(DOTATATE, GaTate) positron emission tomography (PET)/computed tomography (CT) …
[HTML][HTML] Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma
Background Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as
monotherapy in the treatment of mantle-cell lymphoma. Complete response rates of 21% …
monotherapy in the treatment of mantle-cell lymphoma. Complete response rates of 21% …